Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial

BACKGROUND: In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with advanced human epidermal growth factor receptor 2...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ANNALS OF ONCOLOGY 2022-03, Vol.33 (3), p.299-309
Hauptverfasser:	Han, H.S, Arun, B.K, Kaufman, B, Wildiers, H, Friedlander, M, Ayoub, J.P, Puhalla, S.L, Bach, B.A, Kundu, M.G, Khandelwal, N, Feng, D, Bhattacharya, S, Maag, D, Ratajczak, C.K, Dieras, V
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!